Detailed Notes on Management of Recurrent UTIs in Women

Introduction

  • Uncomplicated Urinary Tract Infection (UTI): Common in women, can significantly affect quality of life.
    • Prevalence: 50%–70% of women experience at least one UTI in their lifetime.
    • Recurrence: 20%–30% of those with one UTI may experience recurrent UTIs.
    • Diagnosis Rate: One-third of women are diagnosed with a UTI at least once by a physician.
    • Age Impact: UTI prevalence increases with age, approximately 1% per decade.

Definition of Recurrent UTI

  • Defined as:
    • At least two UTIs within six months
    • At least three UTIs within twelve months
  • Classification of Recurrence:
    • Unresolved Bacteriuria: Caused by inadequate antibiotic therapy.
    • Persistent Bacterial Infection: Fails to respond to appropriate antibiotics after 48 hours.
    • Relapse: Same organism causing re-infection within 1–2 weeks after treatment.
    • Reinfection: Infection by a different organism or same organism after more than 2 weeks.

Pathophysiology of UTIs in Women

  • Normal Flora:
    • Composed predominantly of Lactobacilli which maintain low vaginal pH, preventing pathogen overgrowth.
  • Alterations occur during the menstrual cycle, increasing susceptibility to uropathogenic bacteria (e.g., E. coli).

Diagnosis of Recurrent UTI

  • Symptoms: Dysuria, increased urinary frequency, urgency, and hematuria (especially without vaginal irritation).
  • History-taking: Important to gather data on urinary symptoms, previous UTIs, recent antibiotic use, and possible risk factors.
  • Urinalysis: Should be performed, ideally from a clean catch to avoid contamination.
    • Culture: Mandatory for recurrent UTIs and symptomatic infections.
  • Threshold for Diagnosis:
    • Symptomatic Patients: 102 CFU/ml
    • Asymptomatic Patients: 105 CFU/ml

Management of Recurrent UTI

Lifestyle and Behavioral Modifications
  • Fluid Intake: >1.5 L/day reduces recurrence risk.
  • Hygiene Practices: Wiping front to back, voiding after intercourse.
  • Risk Factors: Avoiding spermicide use is advisable as it increases UTI risk.
Antibiotics
  • Overuse leads to antibiotic resistance; guidelines for proper indications and dosages are necessary.
  • Treatment for Uncomplicated UTIs:
    • Antibiotics: Nitrofurantoin, TMP-SMX (Trimethoprim-Sulfamethoxazole), Fosfomycin.
    • Recommended durations: For nitrofurantoin – 5 days; TMP-SMX – 3 days; Fosfomycin – single dose.
Antibiotic Prophylaxis
  • Can reduce UTI recurrence in pre- and post-menopausal women.
    • Concerns regarding long-term use: Possible resistance and side effects.
  • Recommended Prophylaxis Options:
    • TMP 100mg daily
    • TMP-SMX 40mg/200mg daily
    • Nitrofurantoin monohydrate 50-100mg daily
    • Cephalexin 125-250mg daily

Non-Antibiotic Prophylaxis

Options Available:
  1. Acupuncture: Mixed efficacy; evidence insufficient to recommend.
  2. Cranberry Products: Some evidence of preventing adherence of bacteria to uroepithelium, but overall effectiveness is debated.
  3. D-mannose: Shows potential to reduce UTI episodes but further studies are needed.
  4. Chinese Herbs: May have benefits in combination with antibiotics for acute treatment, but high-quality studies are lacking.
  5. Vaginal Estrogen: Recommended in post-menopausal women due to its positive effects on vaginal flora and UTI prevention.
  6. Hyaluronic Acid ± Chondroitin Sulfate: Can be effective for recurrent UTIs based on some meta-analyses.
  7. Probiotics: Lactobacillus strains may help restore vaginal flora.
  8. Vitamin C & D: Vitamin C can acidify urine; Vitamin D may enhance immune responses.
  9. Electrofulguration: A therapeutic intervention under study for chronic recurrent UTIs.
  10. Vaccines: Emerging therapies like Uro-Vaxom and MV140 show promise but require more data to confirm efficacy.

Conclusion

  • Clinicians must take detailed histories and conduct thorough examinations for potential complications.
  • Urine cultures are crucial for diagnosing recurrent UTIs before initiating antibiotic therapy.
  • Options for management include both antibiotic and non-antibiotic prophylactic measures, particularly focusing on lifestyle changes, behavioral modifications, and newer therapies such as vaccines.
  • Long-term data on innovative treatments are necessary for conclusive efficacy validation.